歡迎光臨源葉生物,登錄 | 注冊 |
當(dāng)前位置: 首頁 > 小分子抑制劑 > CellCycle/Checkpoint > PD0332991 HCl

瀏覽歷史

S80973

PD0332991 HCl

源葉(MedMol) 99%
  • 英文名:
  • PD0332991 HCl
  • 別名:
  • 6-乙酰基-8-環(huán)戊基-5-甲基-2-[[5-(1-哌嗪基)-2-吡啶基]氨基]吡啶并[2,3-d]嘧啶-7(8H)-酮鹽酸鹽
  • CAS號:
  • 827022-32-2
  • 分子式:
  • C24H29N7O2·HCl
  • 分子量:
  • 483.99
  • 核磁/質(zhì)譜:
品牌貨號產(chǎn)品規(guī)格價格(RMB) 庫存(上海) 北京 武漢 南京 數(shù)量計量單位 加入購物車...
源葉(MedMol) S80973-5mg 99% ¥200.00元 >10 - - - EA 加入購物車
源葉(MedMol) S80973-10mg 99% ¥350.00元 >10 - - - EA 加入購物車
源葉(MedMol) S80973-25mg 99% ¥500.00元 >10 - - - EA 加入購物車
源葉(MedMol) S80973-100mg 99% ¥1200.00元 >10 - - - EA 加入購物車
大包裝詢價

提交您的電話號碼并同意《個人信息授權(quán)與保護(hù)申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻(xiàn)

質(zhì)檢證書(COA)

摩爾濃度計算器

相關(guān)產(chǎn)品

  • 提示:詳情請下載說明書。
  • 產(chǎn)品描述: Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma
  • 靶點(diǎn): Cdk4/cyclin D3:9 nM (IC50);Cdk4/cyclin D1:11 nM (IC50);Cdk6/cyclin D2:16 nM (IC50);DYRK1A:2000 nM (IC50);MAPK:8000 nM (IC50);CDK
  • 體內(nèi)研究:
    Palbociclib monohydrochloride (oral adminstration, 75 or 150 mg/kg, daily for 14 days) produces rapid tumor regressions and delays tumor growth. Palbociclib monohydrochloride (oral adminstration, 90 mg/kg, daily for 12 days) reduces Treg numbers and the Treg:CD8 ratio in the spleen and lymph nodes in tumor-free mice, demonstrating the tumor-independent effects. Palbociclib monohydrochloride (oral administration, 100 mg/kg, daily for 1 week) has potent antitumour effects in genetically engineered mosaic mouse model of liver cancer
  • 參考文獻(xiàn):
    1. Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. 2. Goel S, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 Aug 24;548(7668):471-475. 3. Richard S Finn, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77. 4. Bollard J, et al. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 2017 Jul;66(7):1286-1296.
  • 溶解性: Soluble  in  DMSO、H2O
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.066 ml 10.331 ml 20.662 ml
    5 mM 0.413 ml 2.066 ml 4.132 ml
    10 mM 0.207 ml 1.033 ml 2.066 ml
    50 mM 0.041 ml 0.207 ml 0.413 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號:

本計算器可幫助您計算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學(xué)研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。